# Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

> **NCT02667574** · PHASE2 · COMPLETED · sponsor: **University Hospital, Lille** · enrollment: 55 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** ERIVEDGE

## Key facts

- **NCT ID:** NCT02667574
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-18
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02667574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02667574, "Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02667574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*